EMA/191215/2021

European Medicines Agency decision

P/0154/2021

of 16 April 2021

on the acceptance of a modification of an agreed paediatric investigation plan for oritavancin (diphosphate) (Orbactiv), (EMEA-001270-PIP01-12-M03) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.

European Medicines Agency decision

P/0154/2021

of 16 April 2021

on the acceptance of a modification of an agreed paediatric investigation plan for oritavancin (diphosphate) (Orbactiv), (EMEA-001270-PIP01-12-M03) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004[1],

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency[2],

Having regard to the European Medicines Agency's decision P/0056/2013 issued on 25 March 2013, the decision P/0096/2017 issued on 11 April 2017 and the decision P/0131/2019 issued on 17 April 2019,

Having regard to the application submitted by Menarini International Operations Luxembourg S.A. on 5 November 2020 under Article 22 of Regulation (EC) No 1901/2006 proposing changes to the agreed paediatric investigation plan with a deferral and proposing a waiver,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 26 February 2021, in accordance with Article 22 of Regulation (EC) No 1901/2006,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

(1) The Paediatric Committee of the European Medicines Agency has given an opinion on the acceptance of changes to the agreed paediatric investigation plan and on the refusal of a waiver.

(2) It is therefore appropriate to adopt a decision on the acceptance of changes to the agreed paediatric investigation plan.

(3) It is therefore appropriate to adopt a decision refusing a waiver.

[1] OJ L 378, 27.12.2006, p.1.
[2] OJ L 136, 30.4.2004, p. 1.

Has adopted this decision:

Article 1

Changes to the agreed paediatric investigation plan for oritavancin (diphosphate)(Orbactiv), powder for concentrate for solution for infusion, age-appropriate dosage form for parenteral use, intravenous use, are hereby accepted in the scope set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices.

Article 2

A waiver for oritavancin (diphosphate)(Orbactiv), powder for concentrate for solution for infusion, age-appropriate dosage form for parenteral use, intravenous use, the details of which are set out in the opinion of the Paediatric Committee the European Medicines Agency annexed hereto, together with its appendices, is hereby refused.

Article 3

This decision is addressed to Menarini International Opernations Luxembourg S.A. 1, Avenue de la Gare, L-1611 1 Luxembourg, Luxembourg.

EMA/PDCO/656604/2020 Corr
Amsterdam, 26 February 2021

Opinion of the Paediatric Committee on the acceptance of a modification of an agreed Paediatric Investigation Plan

EMEA-001270-PIP01-12-M03

Scope of the application

Active substance(s):

Oritavancin (diphosphate)

Invented name:

Orbactiv

Condition(s):

Treatment of acute bacterial skin and skin structure infections

Authorised indication(s):

See Annex II

Pharmaceutical form(s):

Powder for concentrate for solution for infusion

Age-appropriate dosage form for parenteral use

Route(s) of administration:

Intravenous use

Name/corporate name of the PIP applicant:

Menarini International Operations Luxembourg S.A.

Information about the authorised medicinal product:

See Annex II

Basis for opinion

Pursuant to Article 22 of Regulation (EC) No 1901/2006 as amended, Menarini International Operations Luxembourg S.A. submitted to the European Medicines Agency on 5 November 2020 an application for modification of the agreed paediatric investigation plan with a deferral as set out in the European Medicines Agency's decision P/0056/2013 issued on 25 March 2013, the decision P/0096/2017 issued on 11 April 2017 and the decision P/0131/2019 issued on 17 April 2019.

The application for modification proposed changes to the agreed paediatric investigation plan and to the deferral and proposed a waiver.

The procedure started on 4 January 2021.

Scope of the modification

Some measures and timelines of the Paediatric Investigation Plan have been modified.

Opinion

1. The Paediatric Committee, having assessed the application in accordance with Article 22 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

   - to agree to changes to the paediatric investigation plan in the scope set out in the Annex I of this opinion;

   - to refuse the granting of a waiver for some of the subsets of the paediatric population and the above mentioned condition(s) as it does not meet the grounds detailed in Article 11(1) of said Regulation.

2. The measures and timelines of the paediatric investigation plan are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annexes and appendix.

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)

1. Waiver

1.1. Condition:

Treatment of acute bacterial skin and skin structure infections

The request for the waiver applied to:

- the paediatric population from birth to less 3 months of age;
- powder for concentrate for solution for infusion, age-appropriate dosage form for parenteral use, intravenous use;
- on the grounds that the specific medicinal product is likely to be unsafe.

The waiver request does not provide evidence to support the following grounds set out in Article 11(1) of Regulation (EC) No 1901/2006 that:

- (a) the specific medicinal product is likely to be ineffective or unsafe in the paediatric population;
- (b) the disease or condition for which the specific medicinal product is intended occurs only in adult populations;
- (c) the specific medicinal product does not represent a significant therapeutic benefit over existing treatments for paediatric patients.

Because:

- the PDCO disagreed with the applicant(s)' argumentation that the specific medicinal product is likely to be ineffective or unsafe;
- the disease or condition for which the specific medicinal product is intended, does occur in the paediatric population(s);
- measures would be justified by the expected therapeutic benefit and clinical trials may be feasible;
- the specific medicinal product may represent a significant therapeutic benefit as the needs are not met;
- clinical studies may fulfil a therapeutic need of the paediatric population.

The waiver request is therefore refused by the PDCO.

2. Paediatric Investigation Plan

2.1. Condition:

Treatment of acute bacterial skin and skin structure infections

2.1.1. Indication(s) targeted by the PIP

Treatment of acute bacterial skin and skin structure infections

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From birth to less than 18 years of age

2.1.3. Pharmaceutical form(s)

Powder for concentrate for solution for infusion

Age-appropriate dosage form for parenteral use

2.1.4. Measures

Area	Number of measures	Description
Quality-related studies	1	**Study 1** Age-appropriate dosage form for parenteral use for the paediatric population from birth to 12 months of age.
Non-clinical studies	0	Not applicable.
Clinical studies	2	**Study 2** Open-label, dose-finding trial to evaluate PK, safety and tolerability of oritavancin single dose infusion in children from birth to less than 18 years of age with diagnosed or suspected bacterial infections receiving antibiotic therapy. **Study 3** Evaluator-blind, randomised, multicentre, single dose, active controlled trial to evaluate safety and tolerability of oritavancin in children from birth to less than 18 years of age with acute bacterial skin and skin structure infections, suspected to be caused by gram-positive pathogens.
Extrapolation, modelling and simulation studies	1	Pop PK and pop PK/PD modelling and simulation study in paediatric patients from birth to less than 18 years of age to inform dosing recommendation of oritavancin in paediatric subjects from birth to less than 18 years.

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety/efficacy issues in relation to paediatric use:	Yes
Date of completion of the paediatric investigation plan:	By July 2023
Deferral for one or more measures contained in the paediatric investigation plan:	Yes

Annex II

Information about the authorised medicinal product

Condition(s) and authorised indication(s):

1. Treatment of acute bacterial skin and skin structure infections

Authorised indication(s):

- Orbactiv is indicated for the treatment of acute bacterial skin and skin structure infections (ABSSSI) in adults

Authorised pharmaceutical form(s):

Powder for concentrate for solution for infusion

Authorised route(s) of administration:

Intravenous use